Shares of Merck & Co. Inc. MRK dropped 0.58% to $114.96 Tuesday, on what proved to be an all-around positive trading session ...

Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today the expansion of the newly ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

Fosamax was acquired in 2021 by Organon, which agreed to indemnify Merck against liability from the lawsuits ... of lawsuits alleging that the company's baby powder and other talc products caused ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Merck & Company (MRK – Research Report), ...

Organon shares have stabilized in recent times, with gradual debt reduction and structural growth allowing for a valuation re ...

A U.S. appeals court on Friday revived more than 500 lawsuits alleging that Merck & Co failed to warn that its osteoporosis ...

Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...